GRADE 3/4 ADVERSE EVENT (AE) COSTS OF NIVOLUMAB PLUS IPILIMUMAB (N plus I) VERSUS NIVOLUMAB PLUS CABOZANTINIB (N plus C) AND PEMBROLIZUMAB PLUS AXITINIB (P plus A) FOR PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA (ARCC)

被引：0
|
作者：
McGregor, B. [1 ]
Geynisman, D. [2 ]
Burotto, M. [3 ]
Porta, C. [4 ]
Suarez, C. [5 ]
Bourlon, M. T. [6 ]
Stwalley, B. [7 ]
Du, E. X. [8 ]
Gu, C. [8 ]
Sendhil, S. [8 ]
Betts, K. A. [8 ]
Huo, S. [7 ]
Choueiri, T. K. [1 ]
机构：
[1] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[2] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[3] Bradford Hill Clin Res Ctr, Santiago, Chile
[4] Univ Pavia, Pavia, Italy
[5] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
[6] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico
[7] Bristol Myers Squibb, Princeton, NJ USA
[8] Anal Grp Inc, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN53
引用
收藏
页码：S28 / S29
页数：2
相关论文
共 50 条
  • [1] TEMPORAL TRENDS IN GRADE 3/4 ADVERSE EVENTS AND ASSOCIATED COSTS OF NIVOLUMAB PLUS CABOZANTINIB (N plus C) VERSUS SUNITINIB (S) FOR PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA (ARCC)
    Geynisman, D.
    McGregor, B.
    Burotto, M.
    Porta, C.
    Suarez, C.
    Bourlon, M. T.
    Stwalley, B.
    Du, E. X.
    Gu, C.
    Yang, X.
    Betts, K. A.
    Huo, S.
    Choueiri, T. K.
    VALUE IN HEALTH, 2021, 24 : S36 - S36
  • [2] Matching-adjusted indirect comparison (MAIC) of health-related quality of life (HRQoL) of nivolumab plus cabozantinib (N plus C) vs pembrolizumab plus axitinib (P plus A) in previously untreated advanced renal cell carcinoma (aRCC)
    Porta, C. G.
    Motzer, R.
    Ejzykowicz, F.
    Blum, S. I.
    Hamilton, M.
    May, J. R.
    Huo, S.
    Kral, P.
    Ivanescu, C.
    Choueiri, T. K.
    Cella, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S692 - S693
  • [3] Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis
    Santoni, Matteo
    Rizzo, Alessandro
    Mollica, Veronica
    Rosellini, Matteo
    Marchetti, Andrea
    Fragomeno, Benedetta
    Battelli, Nicola
    Massari, Francesco
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (01) : 45 - 51
  • [4] Characterization of response to nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214
    Rini, B. I.
    Tannir, N. M.
    Escudier, B.
    McDermott, D. F.
    Grimm, M-O.
    Porta, C.
    Powles, T.
    Kollmannsberger, C. K.
    Gurney, H. P.
    Tykodi, S. S.
    Harrison, M.
    Heng, D. Y. C.
    Gruenwald, V.
    Choueiri, T. K.
    Mekan, S.
    McHenry, M. B.
    Hammers, H. J.
    Motzer, R. J.
    George, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
    McGregor, Bradley
    Geynisman, Daniel M.
    Burotto, Mauricio
    Suarez, Cristina
    Bourlon, Maria T.
    Barata, Pedro C.
    Gulati, Shuchi
    Huo, Stephen
    Ejzykowicz, Flavia
    Blum, Steven I.
    Del Tejo, Viviana
    Hamilton, Melissa
    May, Jessica R.
    Du, Ella X.
    Wu, Aozhou
    Kral, Pavol
    Ivanescu, Cristina
    Chin, Andi
    Betts, Keith A.
    Lee, Chung-Han
    Choueiri, Toni K.
    Cella, David
    Porta, Camillo
    EUROPEAN UROLOGY ONCOLOGY, 2023, 6 (03): : 339 - 348
  • [6] Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the UK Perspective
    De Mello, Ramon Andrade
    Ayoub, Emili
    Castelo-Branco, Pedro
    De Almeida Zia, Victor Andre
    Savio, Andre
    Pozza, Daniel Humberto
    Tadokoro, Hakaru
    Teich, Nelson
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [7] A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma
    Shay, Rebecca
    Nicklawsky, Andrew
    Gao, Dexiang
    Lam, Elaine T.
    CLINICAL GENITOURINARY CANCER, 2021, 19 (04) : 370 - +
  • [8] Efficacy outcomes of nivolumab plus cabozantinib versus pembrolizumab plus axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).
    McGregor, Bradley Alexander
    Geynisman, Daniel M.
    Burotto, Mauricio
    Porta, Camillo
    Rodriguez, Cristina Suarez
    Bourlon, Maria Teresa
    Barata, Pedro C.
    Gulati, Shuchi
    Stwalley, Brian
    Del Tejo, Viviana
    Du, Ella X.
    Wu, Aozhou
    Chin, Andi
    Betts, Keith A.
    Huo, Stephen
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    Choueiri, Toni K.
    Powles, Thomas
    Albiges, Laurence
    Burotto, Mauricio
    Szczylik, Cezary
    Zurawski, Bogdan
    Ruiz, Eduardo Yanez
    Maruzzo, Marco
    Zaizar, Alberto Suarez
    Fein, Luis E.
    Schutz, Fabio A.
    Heng, Daniel Y. C.
    Wang, Fong
    Mataveli, Fabio
    Chang, Yu-Lin
    van Kooten Losio, Maximiliano
    Suarez, Cristina
    Motzer, Robert J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (19): : 1767 - 1778
  • [10] Nivolumab plus cabozantinib for advanced renal cell carcinoma
    Benjamin, David J.
    Nolla, Kyle
    Cella, David
    FUTURE ONCOLOGY, 2022, 18 (39) : 4351 - 4359
12345